DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Yuki, Dai ^a,b   Sugiura, Yuki ^a,c   Zaima, Nobuhiro ^a,d   Akatsu, Hiroyasu ^e,f   Takei, Shiro ^a,c   Yao, Ikuko ^a,c   Maesako, Masato ^g   Kinoshita, Ayae ^g   Yamamoto, Takayuki ^e   Kon, Ryo ^b   Sugiyama, Keikichi ^b,h   Setou, Mitsutoshi ^a,c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LION CORPORATION   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d KINKI UNIVERSITY   (Japan)

^e Choju Medical Institute Fukushimura Hospital   (Japan)

^f NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DLG4 PROTEIN, HUMAN; DOCOSAHEXAENOIC ACID; MEMBRANE PROTEIN; PHOSPHATIDYLCHOLINE; SIGNAL PEPTIDE; SYNAPTOPHYSIN; SYP PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AUTOPSY; BRAIN CHEMISTRY; CELL DEATH; CHEMISTRY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; GRAY MATTER; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; NERVE CELL; PATHOLOGY; SYNAPSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOPSY; BRAIN CHEMISTRY; CELL DEATH; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; FEMALE; GENE EXPRESSION; GRAY MATTER; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NEURONS; PHOSPHATIDYLCHOLINES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SYNAPSES; SYNAPTOPHYSIN;

EID: 84923268372     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07130     Document Type: Article

References (51)

1. Jicha, G. A. & Carr, S. A. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J. Alzheimers. Dis. 19, 253-272 (2010).
2. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
3. Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486 (1991).
4. Selkoe, D. J. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem. Res. 28, 1705-1713 (2003).
5. Tomiyama, T. et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 30, 4845-4856 (2010).
6. Cavallucci, V., D'Amelio, M. & Cecconi, F. Ab toxicity in Alzheimer's disease. Mol. Neurobiol. 45, 366-378 (2012).
7. Ma, T. & Klann, E. Amyloid b: linking synaptic plasticity failure to memory disruption in Alzheimer's disease. J. Neurochem. 120, 140-148 (2012).
8. Nitsch, R. M. et al. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. U S A 89, 1671-1675 (1992).
9. Pettegrew, J. W., Panchalingam, K., Hamilton, R. L. & McClure, R. J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 26, 771-782 (2001).
10. Grimm, M. O. et al. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A. 1218, 7713-7722 (2011).
11. Stubbs, C. D. & Smith, A. D. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim. Biophys. Acta 779, 89-137 (1984).
12. Kim, H. Y. Novel metabolism of docosahexaenoic acid in neural cells. J. Biol. Chem. 282, 18661-18665 (2007).
13. Burke, J. E. & Dennis, E. A. Phospholipase A2 biochemistry. Cardiovasc. Drugs Ther. 23, 49-59 (2009).
14. Lukiw, W. J. et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115, 2774-2783 (2005).
15. Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U S A 106, 4012-4017 (2009).
16. Meyer-Luehmann, M. et al. A reporter of local dendritic translocation shows plaque-related loss of neural system function in APP-transgenic mice. J. Neurosci. 29, 12636-12640 (2009).
17. Gómez-Isla, T. et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24 (1997).
18. Giannakopoulos, P. et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500 (2003).
19. Scheff, S. W., Price, D. A., Schmitt, F. A., Scheff, M. A. & Mufson, E. J. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 24, 547-557 (2011).
20. Cullen, K. M. et al. Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience 78, 641-652 (1997).
21. Masliah, E. et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174, 67-72 (1994).
22. Love, S. et al. Premorbid effects of APOE on synaptic proteins in human temporal neocortex. Neurobiol. Aging 27, 797-803 (2006).
23. Sultana, R., Banks, W. A. & Butterfield, D. A. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J. Neurosci. Res. 88, 469-477 (2010).
24. Patti, G. J. et al. Detection of carbohydrates and steroids by cation-enhanced nanostructure-initiator mass spectrometry (NIMS) for biofluid analysis and tissue imaging. Anal. Chem. 82, 121-128 (2010).
25. Schwartz, S. A. & Caprioli, R. M. Imaging mass spectrometry: viewing the future. Methods Mol. Biol. 656, 3-19 (2010).
26. Tucker, K. R., Li, Z., Rubakhin, S. S. & Sweedler, J. V. Secondary ion mass spectrometry imaging of molecular distributions in cultured neurons and their processes: comparative analysis of sample preparation. J. Am. Soc. Mass Spectrom. 23, 1931-1938 (2012).
27. Sugiura, Y. et al. Visualization of the cell-selective distribution of PUFA-containing phosphatidylcholines in mouse brain by imaging mass spectrometry. J. Lipid Res. 50, 1776-1788 (2009).
28. Matsumoto, J. et al. Abnormal phospholipids distribution in the prefrontal cortex from a patient with schizophrenia revealed by matrix-assisted laser desorption/ionization imaging mass spectrometry. Anal. Bioanal. Chem. 400, 1933-1943 (2011).
29. Veloso, A. et al. Distribution of lipids in human brain. Anal. Bioanal. Chem. 401, 89-101 (2011).
30. Jacobs, D. et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 44, 1215-1220 (1994).
31. Hermansson, M. et al. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study. J. Neurochem. 95, 609-617 (2005).
32. O'Brien, J.S. & Sampson, E.L.Lipid compositionofthe normal human brain: gray matter, white matter, and myelin. J. Lipid Res. 6, 537-544 (1965).
33. Jack, C. R. Jr. et al Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
34. Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers. Dement. 7, 280-292 (2011).
35. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
36. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
37. El-Husseini, A. E., Schnell, E., Chetkovich, D. M., Nicoll, R. A. & Bredt, D. S. PSD-95 involvement in maturation of excitatory synapses. Science 290, 1364-1368 (2000).
38. Vickers, C. A. et al. Neurone specific regulation of dendritic spines in vivo by post synaptic density 95 protein (PSD-95). Brain Res. 1090, 89-98 (2006).
39. Radwanska, K. et al. Mechanism for long-term memory formation when synaptic strengthening is impaired. Proc. Natl. Acad. Sci. U S A 108, 18471-18475 (2011).
40. Calon, F. et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645 (2004).
41. Garcia, M. C., Ward, G., Ma, Y. C., Salem, N. Jr. & Kim, H. Y. Effect of docosahexaenoic acid on the synthesis of phosphatidylserine in rat brain in microsomes and C6 glioma cells. J. Neurochem. 70, 24-30 (1998).
42. Hamilton, L., Greiner, R., Salem, N. Jr. & Kim, H. Y. n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids 35, 863-869 (2000).
43. Wurtman, R. J. et al. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. 1088, 83-92 (2006).
44. Sakamoto, T., Cansev, M. & Wurtman, R. J. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 1182, 50-59 (2007).
45. Mucke, L. et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
46. Maesako, M. et al. Environmental enrichment ameliorated high-fat diet-induced Ab deposition and memory deficit in APP transgenic mice. Neurobiol. Aging 33, 1011.e11-23 (2012).
47. Moolman, D. L., Vitolo, O. V., Vonsattel, J. P. & Shelanski, M. L. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 33, 377-387 (2004).
48. Ma, T. et al. Amyloid b-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci. 31, 5589-5595 (2011).
49. Montine, K. S. et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids 128, 117-124 (2004).
50. Schwartz, S. A., Reyzer, M. L. & Caprioli, R. M. Direct tissue analysis using matrixassisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. J. Mass Spectrom. 38, 699-708 (2003).
51. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509 (1957).